Abattis Bioceuticals Corp. engages in the aggregation, integration, and investment in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-04-09. The firm aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. The company operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. The company offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. The company is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Follow-Up Questions
¿Quién es el CEO de Abattis Bioceuticals Corp?
Mr. Robert Abenante es el Chief Executive Officer de Abattis Bioceuticals Corp, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción ATTBF?
El precio actual de ATTBF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Abattis Bioceuticals Corp?
Abattis Bioceuticals Corp pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Abattis Bioceuticals Corp?
La capitalización bursátil actual de Abattis Bioceuticals Corp es $477.79999999999995
